NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has regained compliance with a Nasdaq listing requirement regarding stockholders' equity.

The firm, which makes microRNA-based diagnostic products, said that it received notification from the Nasdaq Listing Qualifications Staff that it is now in compliance with a requirement that it have $2.5 million in stockholders' equity in order to remain listed on the Nasdaq Capital Market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.